Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HBV-MPL vaccine 208129 · 7 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | HBV-MPL Lot A |
| Group B | EXPERIMENTAL | HBV-MPL Lot B |
| Group C | EXPERIMENTAL | HBV-MPL Lot C |
| Group D | ACTIVE_COMPARATOR | Engerix™-B |
| Group A1 | ACTIVE_COMPARATOR | Non-responders to vaccination after at least 7 previous injections |
| Group A2 | EXPERIMENTAL | Non-responders to vaccination after at least 7 previous injections |
| Group B1 | ACTIVE_COMPARATOR | Vaccine-responders requiring a booster dose |
| Group B2 | EXPERIMENTAL | Vaccine-responders requiring a booster dose |
| Group C1 | ACTIVE_COMPARATOR | Volunteers participating in the hospital's vaccination program |
| Group C2 | EXPERIMENTAL | Volunteers participating in the hospital's vaccination program |
| Group D1 | ACTIVE_COMPARATOR | Unvaccinated haemodialysis patients |
| Group D2 | EXPERIMENTAL | Unvaccinated haemodialysis patients |
| Name | Type | Description |
|---|---|---|
| HBV-MPL vaccine 208129 | BIOLOGICAL | 3 consecutive lots; 3-dose intramuscular injection |
| Engerix™-B | BIOLOGICAL | 3-dose intramuscular injection |
Inclusion Criteria: * A male or female between, and including, 15 and 50 years of age at the time of the first vaccination. * Written informed consent obtained from the subject/ from the parents or guardians of the subject where applicable * Free of obvious health problems as established by medical...
HBV-MPL vaccine 208129 is an investigational vaccine being developed for the prevention of Hepatitis B. It is currently in Phase 3 clinical development and has been studied in several patient populations, including pre-liver transplant patients, healthy volunteers, non-responders to existing vaccines, and haemodialysis patients.
HBV-MPL vaccine 208129 is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The company has conducted multiple clinical trials to evaluate the vaccine's immunogenicity and safety in different populations.
HBV-MPL vaccine 208129 is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The development program includes both Phase 3 and Phase 1 trials, with all seven completed trials involving a total of 3,092 participants.
HBV-MPL vaccine 208129 has been studied in seven completed clinical trials. Key trials include NCT00697554 in pre-liver transplant patients, NCT00697749 in healthy volunteers with the HLA-DQ2 genotype, NCT00698061 comparing it to Engerix-B in non-responders, and NCT00699231 in haemodialysis patients.
HBV-MPL vaccine 208129 is a vaccine designed to stimulate the immune system to produce a protective response against the Hepatitis B virus. It contains an adjuvant to enhance immunogenicity, and it has been evaluated in randomized, double-blind, active-controlled trials to assess its ability to generate an immune response.
No, HBV-MPL vaccine 208129 is not the same as Engerix-B. Engerix-B is a comparator vaccine used in clinical trials to evaluate the immunogenicity and safety of HBV-MPL vaccine 208129. The two vaccines have been directly compared in studies involving non-responders and haemodialysis patients.